Xanthine Oxidase Inhibitor — Urate-Lowering Therapy
Pregnancy: Avoid in pregnancy; limited safety data
Allopurinol
Brand names: Zyloric
Adult dose
Dose: 100 mg once daily initially, increasing to 100-900 mg/day
Route: Oral
Frequency: Once daily (after food)
Max: 900 mg/day
Target serum urate under 360 micromol/L (under 300 micromol/L for tophaceous gout). Titrate up every 4 weeks
Paediatric dose
Dose: Seek specialist opinion N/A/kg
Route: Oral
Frequency: Seek specialist opinion
Max: Seek specialist opinion
Seek specialist opinion
Dose adjustments
Renal
Critical: eGFR 30-59: max 100-200 mg/day; eGFR 10-29: 100 mg on alternate days; eGFR under 10: 100 mg at longer intervals — dose carefully, risk of DRESS/SJS at high doses in renal impairment
Hepatic
Reduce dose in hepatic impairment
Paediatric weight-based calculator
Seek specialist opinion
Clinical pearls
- Never start during an acute gout attack — wait until attack fully resolved; initiate colchicine or NSAID prophylaxis to cover first 6 months of ULT
- HLA-B*5801 screening recommended in Han Chinese, Korean, and Thai patients before starting — high risk of severe SJS/DRESS in these populations
- Azathioprine interaction is dangerous and potentially fatal — check all medications before prescribing; if combination unavoidable, reduce azathioprine dose by 75% and monitor FBC closely
- Renal dosing in elderly is critical — most elderly patients have eGFR under 60; start at 50-100 mg and titrate slowly
- NICE CG177: Allopurinol is first-line ULT; check serum urate every 4 weeks during titration, then annually
Contraindications
- Do not start during acute gout attack (will prolong attack)
- Hypersensitivity to allopurinol — HLA-B*5801 genotype strongly associated with severe cutaneous reactions
Side effects
- Rash (stop immediately — can progress to SJS or DRESS)
- GI upset
- Acute gout flare on initiation
- Hepatotoxicity (rare)
- DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms)
Interactions
- Azathioprine / mercaptopurine (allopurinol inhibits xanthine oxidase — dramatically increases toxicity; reduce azathioprine dose by 75%)
- Warfarin (enhanced anticoagulant effect)
- Ampicillin / amoxicillin (increased rash rate)
- ACE inhibitors (increased risk of hypersensitivity reactions)
Monitoring
- Serum urate (target under 360 micromol/L)
- eGFR and renal function
- LFTs
- FBC (if on azathioprine)
- Skin (rash — stop immediately)
Reference: BNFc; BNF 90; NICE CG177 (Gout); BSR Gout Guidelines 2017; MHRA HLA-B*5801 guidance. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- DAPT Score for Dual Antiplatelet Therapy Duration · Antiplatelet Therapy
- ACC/AHA Pooled Cohort Equations (ASCVD Risk) · Cardiovascular Risk
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- DAPT Decision Tool (Ticagrelor vs Clopidogrel) · Antiplatelet Therapy
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Travis Criteria for Severe Ulcerative Colitis · Inflammatory Bowel Disease
Drugs
Pathways
- Falls Assessment in Older Adults · NICE CG161 2013
- Delirium Outside ICU · NICE CG103
- Comprehensive Geriatric Assessment (CGA) · BGS / NICE
- Delirium Assessment and Management · NICE CG103 2010
- Frailty Recognition and Management · BGS Frailty Framework / NHS NHSE
- Polypharmacy and Medicines Optimisation · STOPP/START v2 2014 / NICE NG5